The American Society of Clinical Oncology (ASCO) has provided a rapid update on its guideline recommendations for 177Lutetium-PSMA-617 (177Lu-PSMA-617) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). In 2014, ASCO published a guideline on systemic therapy for patients with mCRPC. The guideline was revised in 2022 to include updated guidance on the use of 177Lu-PSMA-617. ...
RLT
Advertisement
Latest News
Drs. Wallis and Sartor highlight issues with the control arm and considerations for treatment sequencing related to PSMAfore.
Dr. Sartor explains in detail the design and methodology, specific findings, nuances, and implications of the PSMAfore trial.
New research sheds light on the safety of (177Lu)–PSMA-617 for patients with mCRPC and poor bone marrow reserve.
The panel shares insights on future advancements in the field.
The panel discussed the "innovative design" of the phase 2 ENZA-p study presented at ESMO 2023.
The panel discusses treatment-related adverse events, including hematologic toxicities, xerostomia, and more.
Advertisement
Expert Interviews
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Drs. Wallis and Sartor highlight issues with the control arm and considerations for treatment sequencing related to PSMAfore.
Dr. Sartor explains in detail the design and methodology, specific findings, nuances, and implications of the PSMAfore trial.
Drs. Joyce and Wallis consider the impact of financial toxicity and containing costs for patients with GU malignancies.
Drs. Pal and Wallis break down the role of the microbiome and response in patients with kidney cancer.
Dr. Prasad presented the results of the ENVISION trial assessing primary chemoablation in patients with LG-IR NMIBC.
Researchers sought to identify the frequency of germline mutations in patients 46 years or younger.
Advertisement
Roundtables
The panel discusses lutetium-177-PSMA for the treatment of advanced prostate cancer and reviews the VISION trial.
Panel experts discuss PSMA-targeting agents currently being assessed, including PSMA-I&T-Lutetium-177.
Advertisement
